The mechanisms which increment vulnerability to COVID-19 infection in patients with DM may occur through ACE inhibitors or angiotensin receptor blockers which modulate ACE2 expression or through compromised immunity and elevated furin levels [314]. The gene discussed is ACE2; the disease is diabetes mellitus.